Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prednisone controlled-release - Horizon Pharma/Vectura

Drug Profile

Prednisone controlled-release - Horizon Pharma/Vectura

Alternative Names: Lodotra; Modified-release prednisone - Horizon Pharma/Merck; NP-01; Prednisone MR tablet - Horizon Pharma/Merck; Rayos; Single-pulse delayed-release (SPDR) low-dose prednisone tablet - Horizon

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nitec Pharma; SkyePharma PLC
  • Developer Horizon Pharma AG; Merck KGaA; Mundipharma International; Rafa Laboratories
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Asthma; Chronic obstructive pulmonary disease; Polymyalgia rheumatica; Psoriatic arthritis; Rheumatoid arthritis
  • Discontinued Nocturnal asthma

Most Recent Events

  • 08 Aug 2019 No development reported - Phase-III for Polymyalgia rheumatica in United Kingdom, Australia, Czech Republic, Spain, Denmark, Germany, Hungary (PO)
  • 31 Jul 2019 Prednisone controlled-release is not yet available for Rheumatoid arthritis in Estonia, Hungary, Iceland, Latvia, Lithuania (PO)
  • 18 Aug 2016 Horizon Pharma receives patent allowance for Prednisone delayed release tablets in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top